Adrian Jubb - Publications

2007-2011 University of Oxford, Oxford, United Kingdom 

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, et al. Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget. 8: 78870-78881. PMID 29108271 DOI: 10.18632/oncotarget.20239  0.759
2017 Oon CE, Bridges E, Sheldon H, Sainson RCA, Jubb A, Turley H, Leek R, Buffa F, Harris AL, Li JL. Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget. PMID 28445154 DOI: 10.18632/oncotarget.16969  0.715
2016 Mehta S, Hughes NP, Li S, Jubb A, Adams R, Lord S, Koumakis L, van Stiphout R, Padhani A, Makris A, Buffa FM, Harris AL. Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. Ebiomedicine. PMID 27474395 DOI: 10.1016/j.ebiom.2016.07.017  0.743
2015 Chen TT, Filvaroff E, Peng J, Marsters S, Jubb A, Koeppen H, Merchant M, Ashkenazi A. MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation. Ebiomedicine. 2: 406-20. PMID 26137585 DOI: 10.1016/J.Ebiom.2015.03.021  0.371
2015 Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, Campbell DA, Zheng W, Dehdashti S, Shen M, Yang N, et al. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research : Bcr. 17: 59. PMID 25902869 DOI: 10.1186/S13058-015-0564-5  0.358
2014 Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, et al. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. The Journal of Pathology. 234: 502-13. PMID 25074413 DOI: 10.1002/Path.4412  0.334
2014 Oon CE, Bridges E, Sheldon H, Sainson RCA, Jubb A, Turley H, Leek R, Buffa F, Li JL, Harris AL. Functional comparison of Notch ligands in tumour angiogenesis Asian Pacific Journal of Tropical Disease. 4: 229. DOI: 10.1016/S2222-1808(14)60523-5  0.72
2013 Blick C, Ramachandran A, Wigfield S, McCormick R, Jubb A, Buffa FM, Turley H, Knowles MA, Cranston D, Catto J, Harris AL. Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. British Journal of Cancer. 109: 50-9. PMID 23778527 DOI: 10.1038/bjc.2013.240  0.721
2013 Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, et al. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3681-92. PMID 23685835 DOI: 10.1158/1078-0432.Ccr-12-3635  0.315
2013 Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle R, Harris AL, Friedman LS, Belvin M, Middleton MR, Blackwood EM, et al. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. Journal of the National Cancer Institute. 105: 606-7. PMID 23535073 DOI: 10.1093/Jnci/Djt054  0.395
2013 Hoeflich K, Ong C, Lyle K, Jubb A, Zhou W, Harris A, Belvin M, Friedman L, Koeppen H, Rudolph J, Staben S. Abstract A067: Targeting p21-activated kinases in breast cancer Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A067  0.501
2012 Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, Long JE, Hamilton P, McNutt A, Kasman I, Nannini MA, Reslan HB, Cao TC, Ho CC, Barck KH, ... ... Jubb AM, et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. The Journal of Pathology. 227: 417-30. PMID 22611036 DOI: 10.1002/Path.4053  0.36
2012 Jubb AM, Sa SM, Ratti N, Strickland LA, Schmidt M, Callahan CA, Koeppen H. Neuropilin-2 expression in cancer. Histopathology. 61: 340-9. PMID 22384800 DOI: 10.1111/j.1365-2559.2012.04224.x  0.312
2012 Jubb AM, Browning L, Campo L, Turley H, Steers G, Thurston G, Harris AL, Ansorge O. Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma. Histopathology. 60: 740-7. PMID 22296176 DOI: 10.1111/j.1365-2559.2011.04138.x  0.681
2012 Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M, Koeppen H. Neuropilin-1 expression in cancer and development. The Journal of Pathology. 226: 50-60. PMID 22025255 DOI: 10.1002/path.2989  0.452
2012 Mehta S, Hughes NP, Jubb AM, Turley H, Han C, Li SP, Taylor NJ, Padhani AR, Adams RF, Makris A, Harris AL. Early changes in angiogenesis and hypoxia following bevacizumab therapy in primary breast cancer. Journal of Clinical Oncology. 30: 1066-1066. DOI: 10.1200/JCO.2012.30.15_SUPPL.1066  0.697
2012 Ong C, Jubb A, Haverty P, Zhou W, Lyle K, Harris A, Belvin M, Friedman L, Koeppen H, Hoeflich KP. Abstract 4004: P21-activated kinases (PAKs) are novel therapeutic targets in human breast cancer Cancer Research. 72: 4004-4004. DOI: 10.1158/1538-7445.Am2012-4004  0.514
2012 Ong CC, Jubb AM, Haverty PM, Zhou W, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. Abstract B8: Targeting p21-activated kinases in human lung cancer Clinical Cancer Research. 18: B8-B8. DOI: 10.1158/1078-0432.12Aacriaslc-B8  0.424
2011 Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. p21-activated kinase 1: PAK'ed with potential. Oncotarget. 2: 491-6. PMID 21653999 DOI: 10.18632/Oncotarget.271  0.413
2011 Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, Curtarello M, Bonanno L, Masiero M, Ribatti D, Stürzl M, Naschberger E, Croner RS, Jubb AM, Harris AL, Koeppen H, et al. Notch3 signalling promotes tumour growth in colorectal cancer. The Journal of Pathology. 224: 448-60. PMID 21598247 DOI: 10.1002/path.2895  0.488
2011 Jubb AM, Cesario A, Ferguson M, Congedo MT, Gatter KC, Lococo F, Mulè A, Pezzella F. Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. British Journal of Cancer. 104: 1877-81. PMID 21540863 DOI: 10.1038/bjc.2011.147  0.58
2011 Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T, Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H, Hoeflich KP. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 7177-82. PMID 21482786 DOI: 10.1073/Pnas.1103350108  0.656
2011 Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 372-81. PMID 21224365 DOI: 10.1158/1078-0432.Ccr-10-1791  0.516
2011 Jubb AM, Strickland LA, Chen DS, Schmidt M, Koeppen H. Abstract 5130: Neuropilin-1 expression in breast, colorectal and lung cancer Cancer Research. 71: 5130-5130. DOI: 10.1158/1538-7445.Am2011-5130  0.378
2010 Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. The Lancet. Oncology. 11: 1172-83. PMID 21126687 DOI: 10.1016/S1470-2045(10)70232-1  0.491
2010 Yang J, Jubb AM, Pike L, Buffa FM, Turley H, Baban D, Leek R, Gatter KC, Ragoussis J, Harris AL. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Research. 70: 6456-66. PMID 20682797 DOI: 10.1158/0008-5472.CAN-10-0413  0.745
2010 Li JL, Jubb AM, Harris AL. Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncology (London, England). 6: 1099-103. PMID 20624122 DOI: 10.2217/fon.10.62  0.682
2010 Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, Blades J, Li JL, Allen P, Leek R, Noguera-Troise I, Gatter KC, Thurston G, Harris AL. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. The American Journal of Pathology. 176: 2019-28. PMID 20167860 DOI: 10.2353/ajpath.2010.090908  0.778
2010 Jubb AM, Buffa FM, Harris AL. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. Journal of Cellular and Molecular Medicine. 14: 18-29. PMID 19840191 DOI: 10.1111/j.1582-4934.2009.00944.x  0.519
2010 Bernaards C, Hegde P, Chen D, Holmgren E, Zheng M, Jubb AM, Koeppen H, Scherer SJ, Chen DS. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. Journal of Clinical Oncology. 28: 10519-10519. DOI: 10.1200/Jco.2010.28.15_Suppl.10519  0.352
2010 Hoeflich K, Ong C, Jubb A, Haverty P, Truong T, Harris A, Belvin M, Friedman L, Blackwood E, Koeppen H. 343 Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of squamous NSCLC cells European Journal of Cancer Supplements. 8: 109. DOI: 10.1016/S1359-6349(10)72050-4  0.353
2009 Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ, Noguera-Troise I, Pezzella F, Gatter KC, Thurston G, Fox SB, et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. British Journal of Cancer. 101: 1749-57. PMID 19844231 DOI: 10.1038/sj.bjc.6605368  0.787
2009 Farquharson MJ, Al-Ebraheem A, Geraki K, Leek R, Jubb A, Harris AL. Zinc presence in invasive ductal carcinoma of the breast and its correlation with oestrogen receptor status. Physics in Medicine and Biology. 54: 4213-23. PMID 19521003 DOI: 10.1088/0031-9155/54/13/016  0.644
2006 Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 217-27. PMID 16365183 DOI: 10.1200/JCO.2005.01.5388  0.371
2005 Strickland LA, Jubb AM, Hongo JA, Zhong F, Burwick J, Fu L, Frantz GD, Koeppen H. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). The Journal of Pathology. 206: 466-75. PMID 15971170 DOI: 10.1002/path.1805  0.35
2004 Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, Koeppen HW, Hillan KJ. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. Journal of Clinical Pathology. 57: 504-12. PMID 15113858 DOI: 10.1136/jcp.2003.012963  0.304
Show low-probability matches.